Autolus Therapeutics plc Restructuring Charges
Autolus Therapeutics plc (AUTL) reported Restructuring Charges of $4.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-11
- Autolus Therapeutics plc restructuring charges for the quarter ending 2026-06-30 was $2.98M.
- Autolus Therapeutics plc restructuring charges for the quarter ending 2026-03-31 was $1.20M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 12 month |
|---|---|---|---|
| 2026-06-30 | $2.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.18M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $2.40M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |